Author

Suzanne Egyhazi Brage

Karolinska InstitutetORCID 0000-0002-0524-2346Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

Alireza AzimiiD· 1 shared Anna VähärautioiD· 1 shared Christian SommeraueriD· 1 shared Dhifaf SarhaniD· 1 shared Fan ZhangiD· 1 shared Felix HaglundiD· 1 shared Fredrik Jerhammar· 1 shared Galina SelivanovaiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alireza AzimiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 18, 2026

Principles of subclonal gene dosage across human cancer

Sólrún Kolbeinsdóttir, Vasilios Zachariadis, Muyi Yang…·Martin Enge

The paper analyzes subclonal gene dosage effects in cancer using DNTR-seq, finding additive and compensatory transcriptional impacts and identifying transient clonality in ovarian and soft tissue sarcomas.

DOI 10.64898/2026.03.15.711906

humanwhole-genome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 4, 2025

Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of BRAF/NRAS Status

Fan Zhang, Lola Boutin, Ishani Das…·Lars‐Gunnar Larsson

This study shows that combining palbociclib and crizotinib enhances senescence and immune recognition in melanoma cells regardless of BRAF/NRAS status, reducing tumor growth.

DOI 10.1101/2025.07.04.663080

mouseimaging

𝕏 PostBluesky